Prescription drug · ANDA
Sucralfate NDC 67296-2147
Sucralfate 1 g/1 · Tablet · Oral · Redpharm Drug
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 67296-2147-4 | 67296214704 | 40 TABLET in 1 BOTTLE (67296-2147-4)Marketed from May 20, 2023 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Sucralfate
- Generic name (nonproprietary)
- sucralfate
- Active ingredients
- Sucralfate — 1 g/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Redpharm Drug
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215705
- Marketing start
- Listing expires
- Other FDA classes
- Organometallic Compounds (Chemical structure)
- Identifiers
- Product ID 67296-2147_4637f5d7-c529-1d00-e063-6394a90a754fSPL ID 4637f5d7-c529-1d00-e063-6394a90a754fSPL set ID 3251e156-4c52-63b3-e063-6294a90a9a95RxCUI 314234UNII XX73205DH5
- Pharmacologic class
- Aluminum Complex
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N467296214704followed by a unit qualifier and the quantityPackage 67296-2147-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Sucralfate tablets are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 215705
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Coupler LLC | 67046-1469 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Viona Pharmaceuticals Inc | 72578-081 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Preferred Pharmaceuticals Inc | 68788-8779 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8653 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Bryant Ranch Prepack | 71335-2461 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Zydus Lifesciences Limited | 70771-1833 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | NuCare Pharmaceuticals, Inc. | 68071-3812 |